Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (NYSE: KVUE) is recognized as the world's largest pure-play consumer health company, boasting an impressive annual revenue of $15 billion. Established as an independent entity in May 2023 after its spin-off from Johnson & Johnson's consumer segment, Kenvue has rapidly distinguished itself in the market. The company's diverse portfolio spans across several key sectors within the consumer health industry, including cough, cold, and allergy care, pain management, face and body care, oral care, and women's health.
Some of the most iconic brands under Kenvue's umbrella include Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. These brands hold significant market positions globally, attributed to their strong brand equity and consumer trust. Despite operating in a highly fragmented and competitive industry, Kenvue's commitment to quality and innovation has kept it ahead of the curve.
Recently, Kenvue has made strides in its environmental, social, and governance (ESG) initiatives. In May 2024, the Science Based Targets initiative (SBTi) validated Kenvue's near-term greenhouse gas (GHG) emissions reduction targets, aligning with the goal to limit global temperature rise to 1.5°C. This validation underscores Kenvue's dedication to sustainability and its mission to advance the well-being of both people and the planet through its Healthy Lives Mission.
Financially, Kenvue maintains a robust position with a clear focus on expanding its product lines and market reach. The company continues to invest in research and development to enhance its product offerings. Strategic partnerships and collaborations are also central to Kenvue's growth strategy, further solidifying its presence in the consumer health sector.
For the latest updates and information on Kenvue's performance, current projects, and recent achievements, investors and stakeholders are encouraged to visit the company's official website and review its filings with the Securities and Exchange Commission.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has announced a 2.5% increase in its quarterly dividend. The company's Board of Directors declared a $0.205 per share dividend on Kenvue common stock for the third quarter of 2024. This increase demonstrates Kenvue's commitment to returning cash to shareholders as part of its capital allocation strategy aimed at enabling sustainable growth and optimizing total shareholder return.
The dividend will be payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024. Kenvue's portfolio includes iconic brands such as Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®, which are science-backed and recommended by healthcare professionals worldwide.
Kenvue (NYSE: KVUE), the leading global consumer health company, will release its second-quarter 2024 financial results on August 6, 2024, before the market opens. The results will cover the quarter ending June 30, 2024.
A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the results. U.S. participants can dial 877-407-8835, while international participants can dial +1 201-689-8779 to join the call. The webcast will be available on Kenvue's investor relations website, with a replay accessible post-event.
Kenvue, known for brands like Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol, emphasizes the importance of everyday care, with products supported by scientific research and healthcare professionals globally.
Kenvue, the world's largest pure-play consumer health company by revenue, has released its first Healthy Lives Mission Report. The report highlights significant progress in Environmental, Social, and Governance (ESG) goals since becoming an independent company. Key achievements include a 26% reduction in Scope 1 and 2 GHG emissions since 2020, increased use of renewable electricity to 65%, and 71% of their packaging being recyclable or refillable. The company also reports gender parity in its global workforce and a commitment to diversity, with 36% of U.S. employees identifying as racial or ethnic minorities. Kenvue continues to develop inclusive products and promote sustainable practices, aiming for long-term positive impacts on people and the planet.
Kenvue (NYSE: KVUE) announced its participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Key executives, including CEO Thibaut Mongon, CFO Paul Ruh, and Group President Carlton Lawson, will engage in a fireside chat on June 4, 2024, at 8:45 a.m. Eastern Time / 2:45 p.m. Central European Time. The session will be webcast live on Kenvue's investor relations website, with a replay available afterward. Kenvue, a leading pure-play consumer health company with renowned brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol, is committed to leveraging everyday care for consumer well-being.
Kenvue (NYSE: KVUE) announced the pricing of its secondary underwritten public offering of 182,329,550 shares of common stock at $20.00 per share, expected to close on May 17, 2024.
Kenvue will not sell any shares or receive proceeds from the offering. Instead, Johnson & Johnson (NYSE: JNJ) is expected to exchange these shares for its indebtedness held by Goldman Sachs & Co. and J.P. Morgan, who will then sell the shares to underwriters.
Post-offering, Johnson & Johnson will no longer own any shares of Kenvue. The offering will be managed by Goldman Sachs, J.P. Morgan, BofA Securities, and others. A registration statement on Form S-1 has been filed and declared effective by the SEC.
Kenvue Inc. (NYSE: KVUE) has announced the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock. The offering involves the exchange of shares between Kenvue and Johnson & Johnson, with Goldman Sachs & Co. and J.P. Morgan acting as selling shareholders. Following the exchange, the selling shareholders will sell the shares to underwriters. Johnson & Johnson will no longer own any shares of Kenvue's common stock after the completion of the offering.
Kenvue Inc. (NYSE: KVUE) reported first quarter 2024 results with a 1.1% increase in net sales to $3.9 billion and 1.9% organic growth. Diluted earnings per share were $0.15, adjusted to $0.28. Gross profit margin expanded to 57.6%, operating income margin was 14.1%. Initiatives were approved to reduce the global workforce by 4% with cost savings of $350 million by 2026. Outlook for 2024 includes a reported net sales growth of 1.0% to 3.0% and adjusted diluted earnings per share in the range of $1.10 - $1.20.
Kenvue Inc. (NYSE: KVUE) has had its near-term greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi), aligning with efforts to limit global temperature rise. The company commits to a 42% reduction in absolute Scope 1 and 2 GHG emissions by 2030 compared to 2020 levels. Additionally, Kenvue aims for 75% of its suppliers to have science-based targets by 2028. This validation underscores the company's dedication to combating climate change and advancing its Healthy Lives Mission, focusing on the well-being of people and the planet.
FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
What is Kenvue Inc.?
When did Kenvue go public?
What are some of Kenvue's well-known brands?
What sectors does Kenvue operate in?
What recent achievements has Kenvue made?
What is Kenvue's Healthy Lives Mission?
How does Kenvue approach ESG initiatives?
What is the financial condition of Kenvue?
How can I find more information about Kenvue's financial performance?
Who can I contact for investor relations at Kenvue?
